HemAffairs holds your monthly dose of policy, regulatory and pharma news with impact on hematology in Europe.

We also keep you abreast of relevant publications and events to keep an eye on. Enjoy the read! 


HemaPolicy covers topics that relate to European Affairs and the advocacy for hematologists in the European context.

FUNDING ALERT: Calls published on ATMPs, T cells and cancer research

In recent weeks, two Calls for proposals were published that offer relevant funding opportunities for hematologists: IMI2 – 18th Call for proposals and Horizon 2020 – Call for cancer research proposals.

Current status of the Clinical Trials Regulation

In 2014 the European Parliament approved the Clinical Trials Regulation (CTR). Five years later, the regulation has not yet become applicable. What is the aim of the ‘new’ regulation, what issues does it address, and why was its application delayed.

EU Elections and Health Policy

2019 will see significant changes within the European institutions, such as a rise of nationalism and Euroscepticism and a set-back of center political parties.

Rolling out CAR T across Europe

Patient-centric treatments such as gene and cell therapies have been a game-changer in tackling hematological disorders. Nonetheless, their development remains slow and erratic, limiting benefit for patients.

Tackling Sickle Cell Disease: the need for a European approach

Learning how to recognize and treat a disease that is relatively new to many parts of Europe, and spreading, is crucial to limit, if not avoid, irreversible impact and provide proper care to patients.